|
Biomarker Assays for Treatment Selection of Advanced Breast Cancer |
0.53 |
03/15/2020 - 12:00am to 03/15/2021 - 12:00am |
|
Biomarker Testing in Non-Small Cell Lung Cancer |
0.87 |
12/17/2019 - 12:00am to 12/17/2020 - 12:00am |
|
Cardiovascular Health and Risk Management in Cancer Survivors |
0.50 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Chronic Lymphocytic Leukemia Patient Management Simulator |
|
06/08/2020 - 12:00am to 06/08/2021 - 12:00am |
|
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers |
1.25 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Current Topics in Management of Non-Muscle Invasive Bladder Cancer |
0.75 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Debate - What is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia: Chemoimmunotherapy or Small Molecule Inhibitor Therapy? |
1.25 |
05/18/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer |
0.75 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Evidence-Based Approaches to Smoking Cessation in Patients with Cancer |
0.50 |
06/16/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Evolution of Immunotherapy and Management of Complex Toxicities |
1.00 |
05/20/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Genetics/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principles |
0.60 |
03/15/2020 - 12:00am to 03/15/2021 - 12:00am |
|
Immune Checkpoint Inhibitor Toxicities |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Immunotherapies in Non-Small Cell Lung Cancer |
1.25 |
12/17/2019 - 12:00am to 12/17/2020 - 12:00am |
|
Implementing Clinical Trials in the Community Setting |
0.50 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |
|
Improving Efficiency and the Patient Experience in the Ambulatory Setting |
1.00 |
06/05/2020 - 12:00am to 03/01/2021 - 12:00am |
Facebook
Twitter
LinkedIn
Forward